Interleukin-1 receptor antagonist deficiency with a novel mutation; Late onset and successful treatment with canakinumab: A case report

Ezgi Ulusoy, Neslihan Edeer Karaca, Hatem El-Shanti, Erhan Kilicoglu, Guzide Aksu, Necil Kutukculer

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Introduction: Interleukin-1 receptor antagonist deficiency is a rare autoinflammatory disease involving neonatal onset of pustulosis, periostitis, and sterile osteomyelitis. The underlying genetic abnormality involves a recessive mutation in IL1RN, which encodes interleukin-1 receptor antagonist. In this case report, we describe a case of a 12-year-old Turkish girl who initially was presented at 1 year of age, older than previously reported children with interleukin-1 receptor antagonist deficiency, and with a novel mutation, p.R26X, in ILR1N. Case presentation: Our patient developed pustular cutaneous lesions at 1 year of age. At the age of 12 years, she was hospitalized for arthralgia of her knees, elbows, and ankles and arthritis of the left knee, with simultaneous pustular cutaneous lesions. She was admitted to the intensive care unit because of septicemia and respiratory insufficiency during follow-up. A skin biopsy of hyperpigmented lesions demonstrated neutrophil infiltration in the epidermis and subepidermal pustular dermatosis. Interleukin-1 receptor antagonist deficiency was suspected, and genetic analysis revealed a homozygous mutation (p.R26X) in IL1RN, which led to a diagnosis of interleukin-1 receptor antagonist deficiency. Treatment with canakinumab (recombinant human anti-human interleukin-1β monoclonal antibody) 150mg subcutaneously once every 6 weeks was initiated. Our patient did not experience further cutaneous lesions or arthritis. Her post-treatment inflammatory markers were normal; she gained weight; and she was able to walk independently. Conclusions: In this case report, we describe a patient with interleukin-1 receptor antagonist deficiency who responded excellently to canakinumab treatment. We believe more awareness is warranted for interleukin-1 receptor antagonist deficiency in children. It is possible that the mutation in our patient was a founder mutation that may lead to diagnosis of additional cases in Turkey.

Original languageEnglish
Article number145
JournalJournal of Medical Case Reports
Volume9
Issue number1
DOIs
Publication statusPublished - 23 Jun 2015

Fingerprint

Mutation
Skin
Arthritis
Knee
Therapeutics
Periostitis
Interleukin-1 Receptors
Neutrophil Infiltration
Arthralgia
Osteomyelitis
Elbow
Rare Diseases
Turkey
Interleukin-1
Skin Diseases
Epidermis
Ankle
Respiratory Insufficiency
Intensive Care Units
canakinumab

Keywords

  • Autoinflammation
  • Canakinumab
  • Interleukin-1 receptor antagonist deficiency

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Interleukin-1 receptor antagonist deficiency with a novel mutation; Late onset and successful treatment with canakinumab : A case report. / Ulusoy, Ezgi; Karaca, Neslihan Edeer; El-Shanti, Hatem; Kilicoglu, Erhan; Aksu, Guzide; Kutukculer, Necil.

In: Journal of Medical Case Reports, Vol. 9, No. 1, 145, 23.06.2015.

Research output: Contribution to journalArticle

Ulusoy, Ezgi ; Karaca, Neslihan Edeer ; El-Shanti, Hatem ; Kilicoglu, Erhan ; Aksu, Guzide ; Kutukculer, Necil. / Interleukin-1 receptor antagonist deficiency with a novel mutation; Late onset and successful treatment with canakinumab : A case report. In: Journal of Medical Case Reports. 2015 ; Vol. 9, No. 1.
@article{ab1a79dc06d64806af6fdf598ca2e220,
title = "Interleukin-1 receptor antagonist deficiency with a novel mutation; Late onset and successful treatment with canakinumab: A case report",
abstract = "Introduction: Interleukin-1 receptor antagonist deficiency is a rare autoinflammatory disease involving neonatal onset of pustulosis, periostitis, and sterile osteomyelitis. The underlying genetic abnormality involves a recessive mutation in IL1RN, which encodes interleukin-1 receptor antagonist. In this case report, we describe a case of a 12-year-old Turkish girl who initially was presented at 1 year of age, older than previously reported children with interleukin-1 receptor antagonist deficiency, and with a novel mutation, p.R26X, in ILR1N. Case presentation: Our patient developed pustular cutaneous lesions at 1 year of age. At the age of 12 years, she was hospitalized for arthralgia of her knees, elbows, and ankles and arthritis of the left knee, with simultaneous pustular cutaneous lesions. She was admitted to the intensive care unit because of septicemia and respiratory insufficiency during follow-up. A skin biopsy of hyperpigmented lesions demonstrated neutrophil infiltration in the epidermis and subepidermal pustular dermatosis. Interleukin-1 receptor antagonist deficiency was suspected, and genetic analysis revealed a homozygous mutation (p.R26X) in IL1RN, which led to a diagnosis of interleukin-1 receptor antagonist deficiency. Treatment with canakinumab (recombinant human anti-human interleukin-1β monoclonal antibody) 150mg subcutaneously once every 6 weeks was initiated. Our patient did not experience further cutaneous lesions or arthritis. Her post-treatment inflammatory markers were normal; she gained weight; and she was able to walk independently. Conclusions: In this case report, we describe a patient with interleukin-1 receptor antagonist deficiency who responded excellently to canakinumab treatment. We believe more awareness is warranted for interleukin-1 receptor antagonist deficiency in children. It is possible that the mutation in our patient was a founder mutation that may lead to diagnosis of additional cases in Turkey.",
keywords = "Autoinflammation, Canakinumab, Interleukin-1 receptor antagonist deficiency",
author = "Ezgi Ulusoy and Karaca, {Neslihan Edeer} and Hatem El-Shanti and Erhan Kilicoglu and Guzide Aksu and Necil Kutukculer",
year = "2015",
month = "6",
day = "23",
doi = "10.1186/s13256-015-0618-4",
language = "English",
volume = "9",
journal = "Journal of Medical Case Reports",
issn = "1752-1947",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Interleukin-1 receptor antagonist deficiency with a novel mutation; Late onset and successful treatment with canakinumab

T2 - A case report

AU - Ulusoy, Ezgi

AU - Karaca, Neslihan Edeer

AU - El-Shanti, Hatem

AU - Kilicoglu, Erhan

AU - Aksu, Guzide

AU - Kutukculer, Necil

PY - 2015/6/23

Y1 - 2015/6/23

N2 - Introduction: Interleukin-1 receptor antagonist deficiency is a rare autoinflammatory disease involving neonatal onset of pustulosis, periostitis, and sterile osteomyelitis. The underlying genetic abnormality involves a recessive mutation in IL1RN, which encodes interleukin-1 receptor antagonist. In this case report, we describe a case of a 12-year-old Turkish girl who initially was presented at 1 year of age, older than previously reported children with interleukin-1 receptor antagonist deficiency, and with a novel mutation, p.R26X, in ILR1N. Case presentation: Our patient developed pustular cutaneous lesions at 1 year of age. At the age of 12 years, she was hospitalized for arthralgia of her knees, elbows, and ankles and arthritis of the left knee, with simultaneous pustular cutaneous lesions. She was admitted to the intensive care unit because of septicemia and respiratory insufficiency during follow-up. A skin biopsy of hyperpigmented lesions demonstrated neutrophil infiltration in the epidermis and subepidermal pustular dermatosis. Interleukin-1 receptor antagonist deficiency was suspected, and genetic analysis revealed a homozygous mutation (p.R26X) in IL1RN, which led to a diagnosis of interleukin-1 receptor antagonist deficiency. Treatment with canakinumab (recombinant human anti-human interleukin-1β monoclonal antibody) 150mg subcutaneously once every 6 weeks was initiated. Our patient did not experience further cutaneous lesions or arthritis. Her post-treatment inflammatory markers were normal; she gained weight; and she was able to walk independently. Conclusions: In this case report, we describe a patient with interleukin-1 receptor antagonist deficiency who responded excellently to canakinumab treatment. We believe more awareness is warranted for interleukin-1 receptor antagonist deficiency in children. It is possible that the mutation in our patient was a founder mutation that may lead to diagnosis of additional cases in Turkey.

AB - Introduction: Interleukin-1 receptor antagonist deficiency is a rare autoinflammatory disease involving neonatal onset of pustulosis, periostitis, and sterile osteomyelitis. The underlying genetic abnormality involves a recessive mutation in IL1RN, which encodes interleukin-1 receptor antagonist. In this case report, we describe a case of a 12-year-old Turkish girl who initially was presented at 1 year of age, older than previously reported children with interleukin-1 receptor antagonist deficiency, and with a novel mutation, p.R26X, in ILR1N. Case presentation: Our patient developed pustular cutaneous lesions at 1 year of age. At the age of 12 years, she was hospitalized for arthralgia of her knees, elbows, and ankles and arthritis of the left knee, with simultaneous pustular cutaneous lesions. She was admitted to the intensive care unit because of septicemia and respiratory insufficiency during follow-up. A skin biopsy of hyperpigmented lesions demonstrated neutrophil infiltration in the epidermis and subepidermal pustular dermatosis. Interleukin-1 receptor antagonist deficiency was suspected, and genetic analysis revealed a homozygous mutation (p.R26X) in IL1RN, which led to a diagnosis of interleukin-1 receptor antagonist deficiency. Treatment with canakinumab (recombinant human anti-human interleukin-1β monoclonal antibody) 150mg subcutaneously once every 6 weeks was initiated. Our patient did not experience further cutaneous lesions or arthritis. Her post-treatment inflammatory markers were normal; she gained weight; and she was able to walk independently. Conclusions: In this case report, we describe a patient with interleukin-1 receptor antagonist deficiency who responded excellently to canakinumab treatment. We believe more awareness is warranted for interleukin-1 receptor antagonist deficiency in children. It is possible that the mutation in our patient was a founder mutation that may lead to diagnosis of additional cases in Turkey.

KW - Autoinflammation

KW - Canakinumab

KW - Interleukin-1 receptor antagonist deficiency

UR - http://www.scopus.com/inward/record.url?scp=84936774298&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84936774298&partnerID=8YFLogxK

U2 - 10.1186/s13256-015-0618-4

DO - 10.1186/s13256-015-0618-4

M3 - Article

AN - SCOPUS:84936774298

VL - 9

JO - Journal of Medical Case Reports

JF - Journal of Medical Case Reports

SN - 1752-1947

IS - 1

M1 - 145

ER -